NL-OMON47958撤回不适用
A multicenter, first-in-human study to investigate a venipuncture device prototype and assess its safety and feasibility - Feasibility of a venipuncture device prototype
Vitestro B.V.0 个研究点目标入组 82 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 发起方
- 入组人数
- 82
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Age *18 years.
- •* Written signed informed consent must be obtained.
- •* Able to participate in this study
排除标准
- •A potential subject who meets any of the following criteria will be excluded
- •from participation in this study:
- •* Unable to follow instructions.
- •* Previous chemotherapy or intravenous drug use
- •* Diseases that are associated with poor vein conditions, such as hemophilia
- •* Coagulation disorders or use of anticoagulants
- •* Contra-indications for venipuncture in the cubital fossa (e.g. due to local
- •skin disease, burns, edema, hematoma, previous lymph node extirpation, an
- •arteriovenous fistula, or a paretic/ paralyzed arm)
- •* Recurrent vasovagal reactions during venipuncture
- •* Tattoos in the cubital fossa
研究者
相似试验
已完成
不适用
An open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of a thorium-227 labeled antibody-chelator conjugate, BAY 2287411 Injection, in patients with solid tumors known to express mesothelimesotheline expressie solide tumoren. (epithelioid mesothelioma, sereuze ovarium carcinoma, pancreas adenocarcinoma).mesothelin positive tumor cells in malignancies with multiple indicationsNL-OMON50671Bayer18
招募中
不适用
Researcher clinical trial to evaluate the satisfaction of experimenters and subjects with using deep body wound epithelial tissue using urethral catheter to prevent urethral stenosis after bladder tumor resection (TURB) through the urethraNeoplasmsKCT0007010Asan Medical Center198
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS IN CHILDREN AFTER KIDNEY TRANSPLANTATION - TWIST studyEUCTR2005-001348-22-DEAstellas Pharma Europe Ltd200
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS IN CHILDREN AFTER KIDNEY TRANSPLANTATION - TWIST studyEUCTR2005-001348-22-SEAstellas Pharma Europe Ltd200
进行中（未招募）
不适用
AN OPEN, RANDOMISED, MULTICENTRE CLINICAL STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF STEROID WITHDRAWAL WITH TACROLIMUS, MYCOPHENOLATE MOFETIL AND DACLIZUMAB AGAINST TACROLIMUS, MYCOPHENOLATE MOFETIL AND STEROIDS IN CHILDREN AFTER KIDNEY TRANSPLANTATION - TWIST studypaediatric renal transplant patientsMedDRA version: 7.0Level: LLTClassification code 10014646EUCTR2005-001348-22-HUAstellas Pharma GmbH200